<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392041</url>
  </required_header>
  <id_info>
    <org_study_id>0220060122</org_study_id>
    <nct_id>NCT00392041</nct_id>
  </id_info>
  <brief_title>Eszopiclone in the Treatment of Insomnia and Fibromyalgia</brief_title>
  <official_title>Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lesley A. Allen, Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other&#xD;
      symptoms of fibromyalgia. It is hypothesized that participants receiving eszopiclone will&#xD;
      report greater improvement in total sleep time, sleep quality, pain, fatigue, physical&#xD;
      functioning, and emotional distress than will those receiving placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibromyalgia (FM) is a prevalent, debilitating, and costly syndrome. Although the&#xD;
      pathophysiology of FM is not yet well-understood, sleep disturbance is a prominent feature of&#xD;
      most theories. Eszopiclone has been approved by the FDA for the treatment of insomnia, but&#xD;
      has not been studied in the treatment of FMS. The purpose is to assess the efficacy of&#xD;
      eszopiclone for the treatment of insomnia and other symptoms of fibromyalgia (FMS) in FMS&#xD;
      patients. Participants will be randomly selected to receive eszopiclone or placebo. It is&#xD;
      hypothesized that participants receiving eszopiclone will report greater improvement in total&#xD;
      sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress than&#xD;
      will those receiving placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Sleep Time (TST) as Recorded in Patient Diaries</measure>
    <time_frame>week 4</time_frame>
    <description>Difference in total sleep time between week 4 and baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wake Time After Sleep Onset (WASO)</measure>
    <time_frame>week 12</time_frame>
    <description>Minutes awake after sleep onset as recorded in patient diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician-rated Overall Severity of Fibromyalgia</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia Impact Questionnaire</measure>
    <time_frame>week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Eszopiclone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>3mg qpm for 12 weeks</description>
    <arm_group_label>Eszopiclone</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 pill qpm for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age 18 through 64.&#xD;
&#xD;
          2. Meets ACR criteria for FMS, as determined by rheumatological examination and a medical&#xD;
             history review.&#xD;
&#xD;
          3. Reports sleep maintenance insomnia (total sleep time of &lt; 6.5 hours or sleep&#xD;
             impairment consisting of 3 of 7 nights per week for a month by history) or sleep onset&#xD;
             latency insomnia (at least 3 of 7 nights of sleep latency &gt; 30 minutes), as well as&#xD;
             clinically significant daytime distress or impairment during the 1 week self&#xD;
             assessment prior to baseline.&#xD;
&#xD;
          4. Has completed 8th grade and is fluent in English.&#xD;
&#xD;
          5. If a female of child bearing potential, the patient must be non-pregnant and either&#xD;
             post-menopausal or using an approved birth control method. Acceptable birth control&#xD;
             methods include: history of tubal ligation, having a male partner who is sterile,&#xD;
             IUDs, birth control pills or other hormonal birth control methods (e.g., birth control&#xD;
             patch, Depo-Provera injections), and double-barrier methods (e.g., condom and foam).&#xD;
&#xD;
          6. Antidepressant medication will be allowed if the patient has been on a stable dose for&#xD;
             at least one month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of traumatic injury, inflammatory rheumatic disease, or infectious or&#xD;
             endocrine-related arthropathy.&#xD;
&#xD;
          2. Evidence of a primary sleep disorder (e.g., significant sleep disordered breathing&#xD;
             (central or obstructive apnea), periodic limb movement disorder, or REM sleep behavior&#xD;
             disorder.&#xD;
&#xD;
          3. Any current, clinically significant medical condition.&#xD;
&#xD;
          4. Pregnancy.&#xD;
&#xD;
          5. Meets DSM-IV criteria for bipolar disorder, psychotic disorder, organic brain&#xD;
             syndrome, or psychoactive substance abuse or dependence.&#xD;
&#xD;
          6. Any current psychiatric disorder that would interfere with study participation&#xD;
             (investigator judgment).&#xD;
&#xD;
          7. Active suicidal ideation.&#xD;
&#xD;
          8. Plans to engage in additional psychotherapy during the study.&#xD;
&#xD;
          9. Concurrent use of benzodiazepines after 6pm or as a sleep aid.&#xD;
&#xD;
         10. Concurrent use of any other sleep aid.&#xD;
&#xD;
         11. Concurrent use of analgesics other than acetaminophen or non-steroidal&#xD;
             anti-inflammatory medication.&#xD;
&#xD;
         12. Concurrent use of any medication that has not been stabilized for at least 1 month&#xD;
             prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lesley A. Allen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2006</study_first_posted>
  <results_first_submitted>January 11, 2016</results_first_submitted>
  <results_first_submitted_qc>December 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Medicine and Dentistry of New Jersey</investigator_affiliation>
    <investigator_full_name>Lesley A. Allen, Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>Insomnia</keyword>
  <keyword>Sleep</keyword>
  <keyword>Eszopiclone</keyword>
  <keyword>Lunesta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eszopiclone</title>
          <description>Eszopiclone: 3mg qpm for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo: 1 pill qpm for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Weeks 5 - 12</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eszopiclone</title>
          <description>Eszopiclone: 3mg qpm for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo: 1 pill qpm for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.58" spread="8.60"/>
                    <measurement group_id="B2" value="46.94" spread="11.14"/>
                    <measurement group_id="B3" value="44.11" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Sleep Time (TST) as Recorded in Patient Diaries</title>
        <description>Difference in total sleep time between week 4 and baseline</description>
        <time_frame>week 4</time_frame>
        <population>Data are reported through week 4, instead of through week 12 as planned, because of the high drop out rate after week 4. Fewer than 50% of participants remained in the study at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone: 3mg qpm for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: 1 pill qpm for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Sleep Time (TST) as Recorded in Patient Diaries</title>
          <description>Difference in total sleep time between week 4 and baseline</description>
          <population>Data are reported through week 4, instead of through week 12 as planned, because of the high drop out rate after week 4. Fewer than 50% of participants remained in the study at week 12.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.72" spread="69.72"/>
                    <measurement group_id="O2" value="13.47" spread="83.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wake Time After Sleep Onset (WASO)</title>
        <description>Minutes awake after sleep onset as recorded in patient diaries</description>
        <time_frame>week 12</time_frame>
        <population>Data collected was of too poor quality to analyze in a meaningful way</population>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone: 3mg qpm for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: 1 pill qpm for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Wake Time After Sleep Onset (WASO)</title>
          <description>Minutes awake after sleep onset as recorded in patient diaries</description>
          <population>Data collected was of too poor quality to analyze in a meaningful way</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality</title>
        <time_frame>week 12</time_frame>
        <population>Data recorded was of too poor quality to analyze in a meaningful way</population>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone: 3mg qpm for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: 1 pill qpm for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality</title>
          <population>Data recorded was of too poor quality to analyze in a meaningful way</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician-rated Overall Severity of Fibromyalgia</title>
        <time_frame>week 12</time_frame>
        <population>Data recorded was of too poor quality to analyze in a meaningful way</population>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone: 3mg qpm for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: 1 pill qpm for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician-rated Overall Severity of Fibromyalgia</title>
          <population>Data recorded was of too poor quality to analyze in a meaningful way</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibromyalgia Impact Questionnaire</title>
        <time_frame>week 12</time_frame>
        <population>Data recorded was of too poor quality to analyze in a meaningful way</population>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>Eszopiclone: 3mg qpm for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: 1 pill qpm for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fibromyalgia Impact Questionnaire</title>
          <population>Data recorded was of too poor quality to analyze in a meaningful way</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eszopiclone</title>
          <description>Eszopiclone: 3mg qpm for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: 1 pill qpm for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lesley Allen, Ph.D.</name_or_title>
      <organization>Princeton University</organization>
      <phone>609-924-9213</phone>
      <email>lesleyaallen@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

